Research Studies
Study Title
SOD1 Arimoclomol Trial (Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial ALS)
Enrollment Status
Completed
Principal Investigators
Michael Benatar, MD, PhD
Study Type
Goals
Enrolling
SOD1 ALS patients
Eligibility
Click to Expand
Study Involvement
Click to Expand
Contact
Links
Primary Funding Source
FDA, ALS Association
Related Publications
Click to Expand
Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, Schoenfeld D. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018 Feb 13;90(7):e565-e574. Epub 2018 Jan 24.
Related Presentations & Lectures
Click to Expand
Benatar M (presenter), Wuu J, Atassi N, Cudkowicz M, Schoenfeld D. Randomized, phase II trial of arimoclomol in rapidly progressive SOD1 ALS. Late-breaking session platform presentation at the 27th International Symposium on ALS/MND, Dublin, Ireland, Dec 7-9, 2016.
Gronka S, Walker M, Wuu J, Stanislaw C, Fanos J, Atassi N, Jaffa M, Andersen P, Cudkowicz M, Benatar M (presenter). Telemedicine to facilitate ALS research. Platform presentation at the 21st International Symposium on ALS/MND, Orlando, FL, Dec 11-13, 2010.
Gronka S, Wuu J, Usher S, Polak M, Benatar M (presenter). Tackling the challenges of ALS from a familial perspective. Platform presentation at the 20th International Symposium on ALS/MND, Berlin, Germany, Dec 4-10, 2009.
Benatar M (invited speaker). Evolving Paradigms in ALS Therapy Development. 147th Annual Meeting of the American Neurological Association. Chicago, IL, Oct 22-25, 2022.
Benatar M (invited speaker). Predictive, Preventive and Therapeutic Studies in Familial ALS. ALS Association Annual Leadership Forum. Orange County, CA, January 2008.